News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
UCB, Inc.'s Xyrem Rejected in EU for Fibromyalgia
March 18, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharma Times -- UCB has suffered a setback with the news that European regulators have turned down Xyrem as a treatment for fibromyalgia.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Rare diseases
Saol To Pitch Ultrarare Disease Drug as “Poster Child” for RDEP Program
December 9, 2025
·
2 min read
·
Heather McKenzie
FDA
CAR-T Developers Will Need Randomized Trials as FDA Eyes Tighter Approval Requirements
December 9, 2025
·
2 min read
·
Tristan Manalac
Policy
As FDA Deploys Agentic AI, Pharma Begins Testing the Next Frontier of Intelligent Automation
December 8, 2025
·
3 min read
·
Jennifer Smith-Parker
Regulatory
In Change That Pushed Pazdur Out, FDA May Lower Clinical Trial Requirements
December 5, 2025
·
2 min read
·
Dan Samorodnitsky
